Welcome to LookChem.com Sign In|Join Free

CAS

  • or

802536-13-6

Post Buying Request

802536-13-6 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

802536-13-6 Usage

Explanation

This is the full chemical name of the compound, which describes its structure and components.

Explanation

The compound contains a pyrazoloquinazoline core structure, which is the central framework of the molecule.

Explanation

It is a chemical compound, which means it is a substance formed from two or more elements chemically bonded together.

Explanation

The compound acts as a potent and selective inhibitor of the enzyme PARP, which is involved in DNA repair.

Explanation

By inhibiting PARP, the compound prevents the repair of damaged DNA, leading to the death of cancer cells.

Explanation

The compound has shown potential anticancer activity in preclinical studies, making it a candidate for further investigation.

Explanation

The compound is being investigated for its potential use in treating different types of cancer due to its unique structure and mechanism of action.

Explanation

The compound's unique structure and mechanism of action make it a promising candidate for the development of new cancer therapies.

Core Structure

Pyrazoloquinazoline

Classification

Chemical Compound

Target Enzyme

Poly(ADP-ribose) polymerase (PARP)

Role in DNA Repair

Inhibition

Anticancer Activity

Promising

Cancer Treatment Potential

Various types of cancer

Development

Novel cancer therapies

Check Digit Verification of cas no

The CAS Registry Mumber 802536-13-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,0,2,5,3 and 6 respectively; the second part has 2 digits, 1 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 802536-13:
(8*8)+(7*0)+(6*2)+(5*5)+(4*3)+(3*6)+(2*1)+(1*3)=136
136 % 10 = 6
So 802536-13-6 is a valid CAS Registry Number.

802536-13-6SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 18, 2017

Revision Date: Aug 18, 2017

1.Identification

1.1 GHS Product identifier

Product name N,1-Dimethyl-8-{[1-(methylsulfonyl)-4-piperidinyl]amino}-4,5-dihy dro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide

1.2 Other means of identification

Product number -
Other names -

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:802536-13-6 SDS

802536-13-6Downstream Products

802536-13-6Relevant articles and documents

Identification of potent pyrazolo[4,3-h]quinazoline-3-carboxamides as multi-cyclin-dependent kinase inhibitor

Traquandi, Gabriella,Ciomei, Marina,Ballinari, Dario,Casale, Elena,Colombo, Nicoletta,Croci, Valter,Fiorentini, Francesco,Isacchi, Antonella,Longo, Antonio,Mercurio, Ciro,Panzeri, Achille,Pastori, Wilma,Pevarello, Paolo,Volpi, Daniele,Roussel, Patrick,Vulpetti, Anna,Brasca, Maria Gabriella

experimental part, p. 2171 - 2187 (2010/08/19)

Abnormal proliferation mediated by disruption of the mechanisms that keep the cell cycle under control is a hallmark of virtually all cancer cells. Compounds targeting complexes between cyclin-dependent kinases (CDKs) and cyclins (Cy) and inhibiting their activity are regarded as promising antitumor agents to complement the existing therapies. An expansion of pyrazolo[4,3-h]quinazoline chemical class oriented to the development of three points of variability was undertaken leading to a series of compounds able to inhibit CDKs both in vitro and in vivo. Starting from the CDK selective but poorly soluble hit compound 1, we succeeded in obtaining several compounds showing enhanced inhibitory activity both on CDKs and on tumor cells and displaying improved physical properties and pharmacokinetic behavior. Our study led to the identification of compound 59 as a highly potent, orally bioavailable CDK inhibitor that exhibited significant in vivo efficacy on the A2780 ovarian carcinoma xenograft model. The demonstrated mechanisms of action of compound 59 on cancer cell lines and its ability to inhibit tumor growth in vivo render this compound very interesting as potential antineoplastic agent.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 802536-13-6